News & Events

Extranet


FP7
HIVINNOV (Grant n°305137) is a collaborative research project supported by the European Union


Dolutegavir approved in Europe

The European Commision has approved on January 21st the ViiV latest integrase inhibitor, Dolutegravir (marketed under the brand name Tivicay).

 

After Raltegravir (Isentress), Dolutegravir (Tivicay) is the second HIV integrase-inhibitor approved. 

 

To read the news report on "HIV & Hepatitis" click here.

 

To read the press release on Viiv Healthcare click here.